Voyager Therapeutics (VYGR) Tops Q1 EPS by 9c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Voyager Therapeutics Provides First Quarter 2016 Investor Update
May 12, 2016 7:00 AM EDTEnrollment Completed in 2nd Cohort of Ongoing Phase 1b Clinical Trial of VY-AADC01 in Advanced Parkinsons Disease
VY-AADC01 Interim Phase 1b Results to be Presented at 20th International Congress of Parkinsons Disease & Movement Disorders in June 2016
CAMBRIDGE, Mass., May 12, 2016 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company developing life-changing treatments for severe diseases of the central nervous system (CNS), today reported its first quarter 2016 financial results and provided an update on its advanced Parkinsons disease program, VY-AADC01. The Company also... More
Voyager Therapeutics to Present at Upcoming Investor Conferences
May 11, 2016 8:01 AM EDTCAMBRIDGE, Mass., May 11, 2016 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company developing life-changing treatments for severe diseases of the central nervous system (CNS), today announced that company management will present at the following upcoming investor conferences in New York City:
Piper Jaffray GenomeRx SymposiumDate: Tuesday, May 17, 2016Â Panel 1 Title: Thinking Smart About CNS Targeting Gene... More